National Psoriasis Foundation

Drug Pipeline

« Back to the pipeline

Company

Kadmon Corporation

Therapeutic Approach

Oral Treatments

Indication

Psoriasis

Mechanism

anti-inflammatory (ROCK2 inhibitor; decreased IL-17)

Phase

Phase II

Get the latest research news and tips on managing your psoriasis and psoriatic arthritis.